Gena Wang
Stock Analyst at Barclays
(2.22)
# 1,061
Out of 4,647 analysts
175
Total ratings
37.18%
Success rate
-0.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $86 | $70.53 | +21.93% | 15 | Oct 4, 2024 | |
| MRNA Moderna | Maintains: Overweight | $155 → $125 | $53.40 | +134.08% | 6 | Sep 16, 2024 | |
| RNA Avidity Biosciences | Initiates: Overweight | $63 | $47.38 | +32.97% | 1 | Aug 28, 2024 | |
| BLUE bluebird bio | Maintains: Overweight | $8 → $4 | $0.51 | +690.98% | 8 | Aug 15, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $18 → $15 | $5.70 | +163.16% | 6 | Aug 14, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $25 → $31 | $39.32 | -21.16% | 11 | Aug 9, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $9 → $7 | $3.29 | +112.77% | 7 | Aug 8, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $226 → $203 | $128.42 | +58.08% | 7 | Aug 8, 2024 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $33 → $31 | $22.74 | +36.32% | 8 | Aug 7, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $67 → $59 | $48.04 | +22.81% | 13 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $7 | $7.95 | -11.95% | 8 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $9.59 | +421.38% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $54.79 | +47.84% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $472 → $509 | $474.91 | +7.18% | 14 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $38.68 | +31.85% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $291 → $295 | $296.48 | -0.50% | 6 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $7.61 | +267.94% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.26 | +444.79% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $3 | $3.65 | -17.81% | 7 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $45.04 | +108.73% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $9 | $1.21 | +643.80% | 2 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $90 | $21.08 | +326.94% | 5 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.14 | -31.51% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $19.79 | +26.33% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.80 | +288.89% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $5.98 | +201.00% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.30 | +26.98% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $70.29 | +12.39% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.84 | +216.90% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.57 | +4,085.69% | 1 | Jan 6, 2017 |
BioMarin Pharmaceutical
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $70.53
Upside: +21.93%
Moderna
Sep 16, 2024
Maintains: Overweight
Price Target: $155 → $125
Current: $53.40
Upside: +134.08%
Avidity Biosciences
Aug 28, 2024
Initiates: Overweight
Price Target: $63
Current: $47.38
Upside: +32.97%
bluebird bio
Aug 15, 2024
Maintains: Overweight
Price Target: $8 → $4
Current: $0.51
Upside: +690.98%
Solid Biosciences
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $5.70
Upside: +163.16%
PTC Therapeutics
Aug 9, 2024
Maintains: Equal-Weight
Price Target: $25 → $31
Current: $39.32
Upside: -21.16%
Editas Medicine
Aug 8, 2024
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.29
Upside: +112.77%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $128.42
Upside: +58.08%
Beam Therapeutics
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $22.74
Upside: +36.32%
CRISPR Therapeutics AG
Aug 6, 2024
Maintains: Equal-Weight
Price Target: $67 → $59
Current: $48.04
Upside: +22.81%
Aug 6, 2024
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $7.95
Upside: -11.95%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $9.59
Upside: +421.38%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $54.79
Upside: +47.84%
Aug 5, 2024
Downgrades: Equal-Weight
Price Target: $472 → $509
Current: $474.91
Upside: +7.18%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $38.68
Upside: +31.85%
Aug 2, 2024
Maintains: Overweight
Price Target: $291 → $295
Current: $296.48
Upside: -0.50%
Aug 2, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $7.61
Upside: +267.94%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $8.26
Upside: +444.79%
Apr 1, 2024
Maintains: Underweight
Price Target: $2 → $3
Current: $3.65
Upside: -17.81%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $45.04
Upside: +108.73%
Aug 9, 2023
Maintains: Overweight
Price Target: $11 → $9
Current: $1.21
Upside: +643.80%
Aug 7, 2023
Maintains: Overweight
Price Target: $86 → $90
Current: $21.08
Upside: +326.94%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.14
Upside: -31.51%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $19.79
Upside: +26.33%
May 13, 2022
Maintains: Overweight
Price Target: $9 → $7
Current: $1.80
Upside: +288.89%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $5.98
Upside: +201.00%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.30
Upside: +26.98%
Aug 6, 2021
Maintains: Overweight
Price Target: $74 → $79
Current: $70.29
Upside: +12.39%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.84
Upside: +216.90%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.57
Upside: +4,085.69%